Brand and Other Names:Zostavax
- Classes: Vaccines, Live, Viral
Dosing & Uses
Dosage Forms & Strengths
- 19,400 PFU/0.65 mL
Varicella-Zoster Virus Infection
0.65 mL (entire content of vial ) injected SC into upper arm as single dose
FDA approved as single dose for adults ≥50 years, regardless of whether they report prior episodes of herpes zoster; although vaccine is FDA-licensed for patients ≥50 years, Advisory Committee on Immunization Practices (ACIP) recommends that vaccination begin at 60 years; up-to-date vaccination schedules available at http://www.cdc.gov/vaccines/schedules/hcp/index.html
Reconstitute vaccine by using diluent supplied, first withdrawing all contents of diluent vial into syringe, then injecting solution into vial of lyophilized vaccine, and finally agitating to mix
Use separate needles and syringes for reconstituting and administration
Administer immediately after reconstitution
Inject total volume of reconstituted vaccine SC into upper arm
Discard if not used within 30 minutes
Serious - Use Alternative
Significant - Monitor Closely
Suspected adverse events after administration of vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS) at 1-800-822-7967
Pain or tenderness
Flulike syndrome (2%)
Upper respiratory tract infection (2%)
Skin disorder (1%)
Necrotizing retinitis (patients on immunosuppressive therapy)
Hypersensitivity to gelatin, neomycin
Not to be administered to immunosuppressed or immunodeficient individuals, including (1) those with a history of primary or acquired immunodeficiency states, leukemia, lymphoma, or other malignant neoplasms affecting bone marrow or lymphatic system; (2) those with AIDS or other clinical manifestations of infection with HIV; (3) those receiving immunosuppressive therapy; (4) those with active tuberculosis
Treatment provision (including epinephrine injection 1:1000) should be available for immediate use
Defer vaccination in patients with active untreated tuberculosis or acute illness
May not protect all vaccine recipients
Not to be given with 23-valent pneumococcal vaccine; concomitant use decreases immunogenicity of varicella-zoster virus (VZV) vaccine
Transmission of vaccine virus may occur between vaccinees and susceptible contacts (rare)
Not indicated for prevention of primary VZV infection (chickenpox)
Pregnancy & Lactation
Pregnancy category: C
Lactation: Unknown whether agent is excreted in breast milk; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Conveys active immunity by stimulating production of endogenously produced antibodies
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs